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Introduction: Brain metastases frequently cause significant mor-
bidity in patients with non-small cell lung cancer (NSCLC).
Sunitinib is a multitargeted inhibitor of tyrosine kinase receptors,
including vascular endothelial growth factor receptors and platelet-
derived growth factor receptors, which has single-agent antitumor
activity in refractory NSCLC. This phase II study evaluated the
antitumor activity and safety of sunitinib in patients with pretreated
NSCLC and irradiated brain metastases.
Methods: Patients received sunitinib 37.5 mg on a continuous daily
dosing schedule. The primary end point was progression-free sur-
vival. Secondary end points included overall survival, patient-re-
ported outcomes, and safety, including risk of intracranial hemor-
rhage (ICH) associated with focal neurological deficit.
Results: Sixty-four patients received sunitinib (median age 61
years), most (83%) had received prior systemic therapy, 63% had
adenocarcinoma, and 19% had squamous cell carcinoma; most
(55%) were never-smokers. Median progression-free survival was
9.4 weeks (90% confidence interval [CI]: 7.5–13.1), and median
overall survival was 25.1 weeks (95% CI: 13.4–35.5). The most
common treatment-emergent (all-causality) nonhematologic toxici-
ties (any grade) were fatigue (38%) and decreased appetite and
constipation (both 25%). The most common grade 3/4 nonhemato-
logic toxicities were dyspnea (9%) and fatigue (8%). Lymphopenia
(20%) and neutropenia (13%) were the most common grade 3/4
hematologic abnormalities. Serious neurologic adverse events oc-
curred in six patients (9%), and none were treatment-related. No
cases of ICH were reported.
Conclusions: Sunitinib administration on a continuous daily dosing
schedule in patients with NSCLC and brain metastases was safe and
manageable, with no increased risk of ICH.
Key Words: Non-small cell lung cancer, Sunitinib, Brain metasta-
ses, Safety.
(J Thorac Oncol. 2011;6: 1260–1266)
Brain metastases develop in more than 25% of patientswith non-small cell lung cancer (NSCLC) at some point
during the course of their disease1,2 and are associated with
significant morbidity, mortality, and poor prognosis.3,4 Ther-
apeutic options include surgery, stereotactic radiosurgery,
whole-brain radiotherapy (WBRT), and chemotherapy. While
surgery and stereotactic radiosurgery may be considered in
highly selected cases, WBRT is commonly used in most
patients. WBRT can stabilize or even improve symptoms;
however, the median overall survival (OS) of treated patients
is approximately 4 months.5
The role of cytotoxic chemotherapy in the treatment of
brain metastases remains unclear as many clinical trials have
excluded patients with brain metastases. Some intracranial
responses have been reported with first-line chemotherapy
regimens including vinorelbine plus gemcitabine and carbo-
platin6 and cisplatin/carboplatin plus gemcitabine,7,8 and with
the addition of WBRT to paclitaxel and cisplatin,9 and cis-
platin and vinorelbine10; however, the role of the blood-brain
barrier in reducing drug access to brain metastases has always
been a concern. Similarly, few clinical trials of targeted
agents have been conducted in patients with brain metastases
although, in a phase II prospective study, single-agent ge-
fitinib showed some activity in 42 NSCLC patients with brain
metastases.11
Early reports suggested that patients with brain metas-
tases may be more susceptible to intracranial hemorrhage
(ICH).12,13 The observations led to NSCLC patients with
brain metastases being excluded from studies of the anti-
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vascular endothelial growth factor (anti-VEGF) monoclonal
antibody, bevacizumab.14–18 However, the incidence of ICH
in studies of antiangiogenic agents including a monoclonal
antibody (bevacizumab) and tyrosine kinase inhibitors
(sunitinib and sorafenib) remains low (3.3%).19–25 Indeed,
the incidence of ICH was the focus of an open-label bevaci-
zumab study that evaluated 106 patients with NSCLC and
brain metastases where no case of ICH was observed.20
Sunitinib malate (SUTENT; Pfizer Inc., La Jolla, CA)
is an oral, multitargeted tyrosine kinase inhibitor of VEGF
receptors -1, -2, and -3, platelet-derived growth factor recep-
tors (PDGFRs) - and -, stem-cell factor receptor (KIT),
FMS-like tyrosine kinase 3 (FLT3), colony-stimulating factor
1 receptor (CSF-1R), and glial cell line-derived neurotrophic
factor receptor (RET) (Pfizer Inc., data on file, 2008).26–29
Sunitinib is approved for the treatment of advanced renal cell
carcinoma (RCC) and imatinib-resistant/-intolerant gastroin-
testinal stromal tumors and has promising single-agent anti-
tumor activity in refractory NSCLC.22,30 Preclinical data
suggest that VEGF signaling is required for the growth of
brain metastases, and that sunitinib is able to penetrate the
blood-brain barrier rapidly due to its low molecular weight
and high lipophilicity.31,32 A phase II, open-label, single-arm
study was designed to assess the antitumor activity and safety
of sunitinib in patients with advanced NSCLC and brain
metastases. In this study, particular attention was given to the
evaluation of neurologic deficit.
METHODS
Study Design
This trial was an open-label, single-arm, phase II study
designed to evaluate the intracranial and systemic antitumor
activity of single-agent sunitinib in patients with NSCLC and
brain metastases who had previously received WBRT and up
to two systemic therapies. The primary end point was pro-
gression-free survival (PFS), and secondary end points in-
cluded overall and intracranial time to progression (TTP),
time to neurologic progression, objective response rate
(ORR), intracranial ORR, OS, 1-year survival, patient-re-
ported outcomes (PRO), and safety.
This study (NCT00372775) was conducted in accor-
dance with the International Conference on Harmonization
Good Clinical Practice guidelines, the Declaration of Hel-
sinki, and applicable local regulatory requirements and laws.
The study was approved by the institutional review board or
independent ethics committee of each participating center,
and all patients gave written, informed consent.
Study Population
Male or female patients aged 18 years or older with
histologically or cytologically proven NSCLC and radiolog-
ically confirmed brain metastases 4 cm in any linear direc-
tion were enrolled. Other inclusion criteria included WBRT
2 weeks before study entry; a maximum of two prior
systemic therapies; evidence of unidimensionally measurable
disease for systemic disease; Eastern Cooperative Oncology
Group (ECOG) performance status 0 or 1; and adequate
organ function. Patients were to have completed all chemo-
therapy, immunotherapy, and radiotherapy 4 weeks before
study entry (WBRT may have occurred 2 weeks before
study entry). Patients who received WBRT and subsequently
developed intracranial recurrence were also enrolled.
Key exclusion criteria included brainstem lesions, spi-
nal cord compression, carcinomatous meningitis, or lepto-
meningeal disease; candidate for definitive therapy for
brain metastases; intracranial or intratumoral hemorrhage;
uncontrollable seizure activity; treatment with potent cy-
tochrome P450 3A4 enzyme inhibitors or inducers 2
weeks before study entry; National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE) grade
3 hemorrhage less than 4 weeks before starting study treatment;
uncontrolled hypertension; oral anticoagulant therapy; history of
myocardial infarction, severe or unstable angina, coronary or
peripheral artery bypass graft, congestive heart failure, cerebro-
vascular accident or pulmonary embolism within 12 months
before study entry; and major surgery or radiation therapy less
than 4 weeks before starting the study treatment.
Treatment Regimen
Patients received sunitinib 37.5 mg on a continuous
daily dosing schedule in 4-week cycles for 13 cycles (1 year)
or until study withdrawal. Dose reduction to 25 mg/d was
permitted for patients experiencing sunitinib-related toxicity.
Patients experiencing grade 1 nonhematologic or grade 2
hematologic toxicity within the first 8 weeks of treatment
could be dose-escalated to 50 mg/d. The study would be
terminated early if three cases of ICH associated with neu-
rologic deficit were reported after confirmation by an inde-
pendent radiological review board.
Assessments
Antitumor activity was evaluated by radiologic tumor
assessments carried out at screening, on cycle 2 day 1, cycle
3 day 1, and every 8 weeks thereafter. Radiologic assessment
was also performed if disease progression was suspected.
Intracranial disease was measured using three-dimensional
thin-slice magnetic resonance imaging (conducted on day 1
of cycles 2 and 3 and odd cycles thereafter, and at end of the
treatment or withdrawal from study), and systemic disease
was measured using magnetic resonance imaging or com-
puted tomography scan.
Overall antitumor efficacy was based on objective tu-
mor assessments performed according to the Response Eval-
uation Criteria in Solid Tumors (RECIST version 1.0; partial
response [PR]  30% decrease in target lesion size; pro-
gressive disease [PD]  20% increase in target lesion
size).33 Intracranial response was assessed using World
Health Organization criteria as RECIST has not been vali-
dated for evaluating brain lesions (PR  50% reduction
from baseline in the sum of the products of all enhancing
tumors and PD  25% increase from smallest size in the
sum of the products of all enhancing tumors or the appear-
ance of any new tumor). However, for overall antitumor
efficacy, unidimensional measurements of brain lesions were
assessed according to RECIST.
PRO was assessed using the self-administered func-
tional assessment of cancer therapy (FACT)/National Com-
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prehensive Cancer Network (NCCN) Lung Symptom Index
(FLSI) and the FACT/NCCN Brain Symptom Index (FBrSI),
in which patients were asked to score questions based on their
impact during the past 7 days. The FLSI comprises six
questions measuring common symptoms affecting lung can-
cer patients, including dyspnea, cough, fatigue, weight loss,
and pain. The FBrSI comprises 15 questions measuring
common symptoms affecting brain tumor patients, including
headaches, seizures, fatigue, nausea, motor dysfunction
(weakness in arms/legs, trouble with coordination), commu-
nication deficit (difficulty finding words/expressing
thoughts), deficiency in physical/role functioning (difficulty
bathing, dressing, eating, etc.), and deficiency in emotional
functioning. Data were collected on days 1 and 15 of the first
two 4-week cycles, on day 1 only in subsequent cycles, at the
end of treatment or withdrawal from the study, and on day 28
post-treatment assessment. Patients completed the question-
naire at the clinic before administration of the study drug or
other clinical activities.
Safety was assessed by monitoring adverse events
(AEs) graded according to NCI CTCAE, version 3.0. Stan-
dard laboratory hematologic and blood chemistry parameters
were assessed at baseline, on day 1 of cycles 2 to 13, and at
the end of treatment. There was an optional assessment point
for both on day 1 of cycle 1 and at 28 days post-treatment.
Hematologic parameters were measured on day 15 of cycles
2 to 4. Thyroid stimulating hormone and coagulation were
assessed at screening and then as clinically indicated there-
after as per standard medical practice.
Statistical Analysis
Data are presented for all patients enrolled in the study
who received 1 dose of study medication. Based on previ-
ous PFS and TTP data from patients with NSCLC with brain
metastases, and the expectation that approximately 25% of
patients will receive study treatment as first-line systemic
therapy after WBRT, it was assumed that a median PFS of 10
weeks would be observed in the study population if treated
with standard of care, and a PFS of 14 weeks would be
considered clinically relevant with sunitinib therapy. Assum-
ing a type I error rate of 5% (one-sided) and a type II error
rate of 20%, a 9-month accrual period, a minimum follow-up
period of 12 months, and a 10% dropout rate, it was estimated
that 60 patients would need to be enrolled. Time to event end
points (PFS, overall and intracranial TTP, and OS) were
summarized using Kaplan-Meier estimates. The number and
percent of subjects achieving objective response (complete
response [CR] or PR) was summarized along with the corre-
sponding exact two-sided 95% confidence interval [CI]. Ex-
ploratory analyses of PRO data were conducted using re-
peated measures mixed models with autoregressive
covariance structure to study changes from baseline at each
subsequent visit. A change was considered meaningful if the
numerical change was more than 5% of the total score (a
minimally clinically important difference) and p  0.10.34
Baseline PRO value was included as a covariate and visit was
used as a class variable. No adjustments were made for
multiple comparisons. All patients with baseline and at least
one postbaseline PRO measurement were included in the
analysis. Descriptive statistics were used to summarize AEs
and other safety data.
RESULTS
Patient Disposition and Baseline Characteristics
Between March 2007 and December 2009, 66 patients
were enrolled and 64 received treatment (61% male; median
age, 61 years [range, 35–77]). Two patients were enrolled but
not treated (one chose alternative treatment and the other had
global deterioration of health status, before receiving study
treatment). Patients had an ECOG performance status of 0/1
(98%) or 2 (2%) (Table 1). The majority of patients had
adenocarcinoma (63%) or squamous cell carcinoma (19%)
and had received prior systemic therapy (83%) and WBRT
(98%). Sixty-four patients were evaluable for safety and 61
were evaluable for overall response.
Patients received sunitinib for a median of two cycles
(range, 1–13), and the median dose administered was 37.5
TABLE 1. Patient Baseline Characteristics
Characteristic Patients (N  64)
Gender, n (%)
Male 39 (61)
Female 25 (39)
Age (yr)
Median 61
Range 35–77
65, n (%) 44 (69)
65, n (%) 20 (31)
ECOG PS, n (%)
0/1 35 (55)/28 (44)
2a 1 (2)
Histology, n (%)
Adenocarcinoma 40 (63)
Squamous cell carcinoma 12 (19)
Large cell carcinoma 2 (3)
Bronchioalveolar carcinoma 1 (2)
Not otherwise specified/other 8 (13)/1 (2)
Smoking status, n (%)
Smoker 9 (14)
Ex-smoker 20 (31)
Never-smoker 35 (55)
Ethnicity, n (%)
Caucasian/other 60 (94)/4 (6)
Prior treatments, n (%)
Whole-brain radiotherapyb 63 (98)
Surgery 57 (89)
Systemic therapy 53 (83)
Number of prior systemic regimens, n (%)c
1 44 (69)
2 8 (13)
3d 1 (2)
a One patient had an ECOG PS of 2 due to protocol deviation.
b One patient did not receive whole-brain radiotherapy due to protocol deviation.
c 11 patients did not receive prior systemic therapy.
d One patient received 3 prior systemic regimen due to protocol deviation.
ECOG PS, Eastern Cooperative Oncology Group performance status.
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mg/d (range, 27–40). At least one dose delay was required in
10 patients (16%) and dose reduction to 25 mg/d occurred in
17 patients (27%), primarily due to AEs. Twenty-nine pa-
tients (45%) required dose interruption and two patients (3%)
had their dose increased to 50 mg/d.
Study discontinuations were primarily due to disease
progression or relapse (n  30, 47%). In addition, eight
patients (13%) discontinued due to AEs, four of which were
considered related to sunitinib (pulmonary embolism, renal
failure, cutaneous rash, and platelets decrease [each n  1]).
Overall Antitumor Activity
Median PFS was 9.4 weeks (90% CI: 7.5–13.1). Median
PFS estimated in a subgroup of patients (n  9) reporting
progressive disease as best response to WBRT was 12.5 weeks
(95% CI: 9.8–24.1). Median TTP was 15.1 weeks (95% CI:
8.4–15.8). Sixty-one patients were evaluable for overall re-
sponse. One patient (1.6%) had a PR and 18 patients (29.5%)
had stable disease (SD) 8 weeks, giving an ORR of 1.6%
(95% CI: 0.0–8.8). Median OS was 25.1 weeks (95% CI:
13.4–35.5). Kaplan-Meier estimates for PFS are shown in Fig-
ure 1, and best percentage change in target tumor lesion size is
shown in Figure 2. There were 10 best changes from baseline in
target lesion size that exceeded the 30% reduction threshold
required to achieve a PR by RECIST (Figure 2). However, with
the exception of the patient with PR mentioned above, target
lesion reductions were not recorded as PRs because reductions
in target lesion size were not confirmed (due to disease progres-
sion or discontinuation from the study), or because in some cases
new lesions were also reported in nontarget lesions and therefore
the overall response was PD not PR.
Intracranial Antitumor Activity
Median time to intracranial progression was 15.4 weeks
(95% CI: 12.1–24.8). Among 23 patients with measurable
intracranial disease at baseline, one patient (4.3%) had an
intracranial PR (also recorded as an overall response) and
seven patients (30.4%) had SD 8 weeks. Baseline charac-
teristics of the patients evaluable for overall antitumor activ-
ity and the patients evaluable for intracranial antitumor ac-
tivity were generally similar—with the exception of smoking
status (14.1% and 34.8% of patients were smokers, respec-
tively).
Patient-Reported Outcomes
Changes from baseline in FLSI and FBrSI and item
scores are presented in Table 2. Both the FBrSI score and
FLSI score remained stable and did not change significantly
from baseline during the treatment period. Meaningful im-
provement was reported in three common symptoms of lung
cancer (cough, weight loss, and dyspnea) during multiple
treatment cycles. In addition, brain symptoms including
“headache” and patients’ “worry that their condition will get
worse” both decreased during multiple treatment cycles.
However, patients also reported worsening in certain symp-
toms in one or more treatment cycles (Table 2).
Safety
All patients who received treatment (N  64) were
evaluable for safety. The most common treatment-emergent
(all-causality) nonhematologic AEs of any grade were fatigue
(n  24, 38%) and decreased appetite and constipation (both
n  16, 25%; Table 3). The most common grade 3/4 AEs
were dyspnea and fatigue (six patients [9%] and five patients
[8%], respectively). Other AEs of interest included hyperten-
sion (n  12 [19%]) and one event of hypothyroidism
(grade 2). Treatment-related nonhematologic grade 4 AEs
occurred in three patients: oral pain, oropharyngeal pain, and
dysphagia (n  1), hemoptysis (n  1), and pulmonary
embolism (n  1). Grade 3/4 hematologic laboratory abnor-
malities are shown in Table 3.
Serious neurologic AEs occurred in six patients (9%):
epilepsy (n  2) and convulsion, cerebral ischemia, inten-
tional self-injury (grade 5), and tremor (each n 1), and none
were judged to be related to sunitinib. No cases of ICH were
reported as confirmed by third-party radiologic review (Rad-
Pharm Inc., Princeton, NJ).
FIGURE 1. Kaplan-Meier estimates for progression-free sur-
vival.
FIGURE 2. Best percentage change from baseline in target
tumor lesion size.
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As of March 2010, 54 patients have died: 48 deaths
were attributed to systemic disease progression, 3 were at-
tributed to AEs (intentional self-injury [suicide], chronic
obstructive pulmonary disease [disease present at screening],
and worsening of respiratory function), and the causes of the
final 3 deaths were unknown. Six of the 10 patients alive at
the end of the study received one regimen containing pem-
etrexed as follow-up systemic therapy; the other four patients
received erlotinib.
DISCUSSION
Brain metastases are a common occurrence in patients
with advanced NSCLC, and patients developing these lesions
may be more susceptible to ICH.14 Clinical data from patients
with central nervous system malignancies have suggested that
sunitinib has a manageable and predictable safety profile in
this setting.31,35,36 To date, this is the largest prospective
clinical trial designed to evaluate the efficacy as well as the
safety of an antiangiogenic agent in NSCLC patients with
brain metastases. Importantly, no cases of ICH due to
sunitinib treatment were observed. Recent studies, including
the phase II PASSPORT study of bevacizumab in 106
NSCLC patients with irradiated brain metastases, reported no
cases of ICH (efficacy was not formally evaluated).20 Simi-
larly, in 37 NSCLC patients with irradiated brain metastases
who were enrolled in the BETA lung study evaluating bev-
acizumab plus erlotinib, no increased risk of cerebral hem-
orrhage was observed.37 Furthermore, the NCCN has since
amended their guidelines to permit the use of bevacizumab in
eligible NSCLC patients with treated brain metastases; how-
ever, at the present time, the American Society of Clinical
Oncology continues to advise against administering bevaci-
zumab to these patients. Our study, combined with the safety
data in the PASSPORT and BETA studies, indicates that
treatment with antiangiogenic agents does not increase the
incidence of ICH in NSCLC patients with irradiated brain
TABLE 2. Functional Assessment of Cancer Therapy (FACT) Lung and Brain Symptom Assessment: Mean Change from
Baseline Scores
Cycle 1 Day 15 Cycle 2 Day 1 Cycle 2 Day 15 Cycle 3 Day 1 Cycle 4 Day 1 Cycle 5 Day 1
Days after start of treatment 14–22 26–37 40–55 56–72 84–72 113–119
Patients, n 36 34 27 23 17 10
FLSI overall index score 0.33 0.38 0.22 0.62 0.19 0.12
Items
I have been short of breath 0.22* 0.22* 0.26* 0.36† 0.43† 0.03
I have a lack of energy 0.10 0.19 0.16 0.10 0.18 0.53†
I have pain 0.23 0.04 0.02 0.09 0.30 0.20
I am losing weight 0.30† 0.32† 0.03 0.04 0.30 0.43*
I have been coughing 0.39† 0.25* 0.14 0.60† 0.02 0.23
I have certain areas of my body where I
experience pain
0.21 0.17 0.23 0.04 0.33 0.07
FBrSI overall index score 0.62 1.19 0.53 1.24 0.45 1.79
Items
I get headaches 0.24† 0.11 0.36† 0.11 0.16 0.03
I have had seizures 0.01 0.18† 0.08 0.06 0.03 0.07
I have weakness in arms or legs 0.11 0.23 0.00 0.42† 0.40* 0.22
I need help caring for myself 0.16 0.21* 0.11 0.19 0.21 0.32
I have lack of energy 0.15 0.27* 0.21 0.19 0.26 0.15
I have difficulty expressing thoughts 0.06 0.03 0.16 0.00 0.01 0.38*
I have trouble with coordination 0.05 0.37† 0.32† 0.25 0.21 0.47†
I get frustrated that I cannot do things 0.28* 0.26 0.10 0.09 0.23 0.05
I have nausea 0.14 0.06 0.32 0.36 0.24 0.10
I am able to find the right word(s) to say what
I mean
0.02 0.22 0.50* 0.41 0.49 0.33
I am losing hope in the fight against my illness 0.02 0.06 0.01 0.01 0.04 0.06
I have trouble meeting needs of family 0.00 0.14 0.03 0.08 0.00 0.12
I worry my condition will get worse 0.18 0.28* 0.45† 0.27 0.49† 0.32
I am afraid of having a seizure 0.12 0.03 0.08 0.24 0.20 0.01
I am able to enjoy life 0.22 0.20 0.27 0.23 0.48† 0.35
Bold scores suggest a meaningful decrease in symptoms while on treatment. Italicized scores suggest a meaningful increase in symptoms while on treatment.
* p  0.10.
† p  0.05.
FLSI, FACT Lung Symptom Index (range 0–24, with higher score indicating better outcome); FBrSI, FACT Brain Symptom Index (range 0–60, with higher score indicating
better outcome). All symptom item scores have a range of 0–4, with higher scores indicating more symptom, except for two items “able to find the right words(s) to say what I mean”
and “able to enjoy life” in which high scores indicate less symptom. A change was considered meaningful if the numerical change was more than 5% of the total score (a minimally
clinically important difference) and p  0.10.34
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metastases. However, patients with advanced NSCLC and
brain metastases should continue to be monitored carefully
when treated with targeted antiangiogenic agents.
In this study, treatment with sunitinib was associated
with only marginal antitumor activity (the primary end point
of this study was not met); however, the PFS of 9.4 weeks,
TTP of 15.1 weeks, and OS of 25.1 weeks were similar to
time-to-event data reported in other studies of patients with
brain metastases. A study of 41 patients with NSCLC and
brain metastases treated with the targeted anti-epidermal
growth factor receptor (anti-EGFR) agent, gefitinib, reported
PFS of 12 weeks and OS of 20 weeks but a superior response
rate of 10% (four PRs).11 Two studies have examined che-
motherapy regimens in patients with brain metastases and
again TTP ranged from 12 to 19 weeks and OS ranged from
21 to 33 weeks, although the response rates were consistently
higher than that reported here (ranging from 28 to 50%).7,9
Comparisons between studies are hampered by differences in
patient populations, such as level of pretreatment (note that
11 patients in the current study received sunitinib as first-line
therapy) and performance status. However, despite the low
ORR (1.6%) in the current study, intracranial antitumor
activity was observed with 1 of 23 patients experiencing an
intracranial PR and 7 experiencing SD. Intracranial responses
and regression of brain metastases after treatment with
sunitinib have also been reported in sunitinib-treated patients
with advanced RCC and metastatic breast cancer.35,38–43
FLSI and FBrSI scores did not change significantly
from baseline throughout the treatment period. During some
treatment cycles, there was meaningful improvement in some
common symptoms associated with lung cancer, including
cough, dyspnea, and weight loss. Patients who were most
able to tolerate treatment may have been more likely to
complete questionnaires in the later cycles of this study,
hence the potential for bias must be considered when inter-
preting these results.
AEs were consistent with those reported in other stud-
ies of single-agent sunitinib, including studies of intermittent
dosing schedules (schedule 4/2; 4 weeks on treatment fol-
lowed by 2 weeks off treatment) in NSCLC22,30 and in RCC
and gastrointestinal stromal tumors.44,45 Fatigue and asthenia
were frequently reported, occurring at any grade in 38% and
17% of patients, respectively. Although some reports have
linked these AEs to hypothyroidism, we observed seven
patients (11%) who were receiving thyroid replacement ther-
apy and had hypothyroidism at study entry. Treatment-emer-
gent hypothyroidism was reported in only one patient (2%)
on study. The patient had no prior history of hypothyroidism,
developed grade 2 hypothyroidism, and received levothyrox-
ine therapy; the AE resolved within 4 weeks.
In this study, sunitinib on a continuous daily dosing
schedule was safe and manageable, and no cases of ICH were
observed. However, given the marginal antitumor activity
reported in this study, no future trials of sunitinib in patients
with NSCLC and brain metastases are planned. Given the
poor prognosis of patients with brain metastases resulting
from NSCLC, new treatment options are needed—particu-
larly as these patients are often excluded from clinical trials.
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